99mtc-trastuzumab: a potential radiopharmaceutical for the evaluation of the over-expression of her2 in tumors.

• In: SIG Nuclear/Radiologic Pharmacy - Poster Session
• At: Salvadore (Brazil) (2006)
• Type: Poster
• Poster code: NR-P-003
• By: SAVIO, Eduardo (Facultad de Química, Montevideo, Uruguay)
• Co-author(s): Cabral, Pablo (Facultad de Ciencias, MONTEVIDEO, Uruguay)
  Robles, Ana (Facultad de Ciencias, MONTEVIDEO, Uruguay)
  Piuma, Lourdes (Facultad de Química, MONTEVIDEO, Uruguay)
  Gambini, Juan Pablo (Facultad de Medicina, MONTEVIDEO, Uruguay)
  Balter, Henia (Facultad de Ciencias, MONTEVIDEO, Uruguay)
  Savio, Eduardo (Facultad de Química, MONTEVIDEO, Uruguay)
  
• Abstract:

  Trastuzumab (Herceptin®) is a monoclonal antibody produced by recombinant DNA technology that binds specifically to the human epidermal growth factor receptor-2- protein (also known as HER2). A consequence of the amplification of gene HER2 is an increase in the expression of protein HER2 in the surface of the tumour cells, which result in a..

The access to the whole abstract and if available the presentation file is available to FIP members and to congress participants of that specific congress. Please login